53 related articles for article (PubMed ID: 8520515)
1. Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2.
Peest D; Leo R; Deicher H
Stem Cells; 1995 Aug; 13 Suppl 2():72-6. PubMed ID: 8520515
[TBL] [Abstract][Full Text] [Related]
2. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
3. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
4. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
6. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
7. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.
Peest D; Leo R; Bloche S; Hein R; Stannat-Kiessling S; Tschechne B; Fett W; Harms P; Hoffmann L; Bartl R
Br J Haematol; 1995 Feb; 89(2):328-37. PubMed ID: 7873383
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
9. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
Verma V; Sharma V; Shrivastava SK; Nadkarni JJ
J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531
[TBL] [Abstract][Full Text] [Related]
10. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.
Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ
Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
13. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
Meehan KR; Wu J; Bengtson E; Hill J; Ely P; Szczepiorkowski Z; Kendall M; Ernstoff MS
Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
[TBL] [Abstract][Full Text] [Related]
14. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of multiple myeloma with LAK cells plus interleukin 2 or interleukin 2 alone].
Togawa A; Sawada S; Amano M; Oshimi K; Satoh H; Takaku H
Rinsho Ketsueki; 1989 May; 30(5):650-8. PubMed ID: 2795879
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
17. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
